You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 14, 2025

CALDOLOR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Caldolor, and what generic alternatives are available?

Caldolor is a drug marketed by Cumberland Pharms and is included in one NDA. There are ten patents protecting this drug.

This drug has fifty-six patent family members in fifteen countries.

The generic ingredient in CALDOLOR is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and forty-three suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Caldolor

A generic version of CALDOLOR was approved as ibuprofen by STRIDES PHARMA on September 24th, 1986.

  Try for Free

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for CALDOLOR?
  • What are the global sales for CALDOLOR?
  • What is Average Wholesale Price for CALDOLOR?
Drug patent expirations by year for CALDOLOR
Drug Prices for CALDOLOR

See drug prices for CALDOLOR

Recent Clinical Trials for CALDOLOR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Yonsei UniversityN/A
St. Joseph's Hospital and Medical Center, PhoenixPhase 2
St. Joseph's Hospital and Medical Center, PhoenixPhase 4

See all CALDOLOR clinical trials

Pharmacology for CALDOLOR

US Patents and Regulatory Information for CALDOLOR

CALDOLOR is protected by ten US patents and one FDA Regulatory Exclusivity.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cumberland Pharms CALDOLOR ibuprofen SOLUTION;INTRAVENOUS 022348-001 Jun 11, 2009 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Cumberland Pharms CALDOLOR ibuprofen SOLUTION;INTRAVENOUS 022348-002 Jun 11, 2009 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Cumberland Pharms CALDOLOR ibuprofen SOLUTION;INTRAVENOUS 022348-002 Jun 11, 2009 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Cumberland Pharms CALDOLOR ibuprofen SOLUTION;INTRAVENOUS 022348-003 Jan 25, 2019 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CALDOLOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cumberland Pharms CALDOLOR ibuprofen SOLUTION;INTRAVENOUS 022348-001 Jun 11, 2009 ⤷  Try for Free ⤷  Try for Free
Cumberland Pharms CALDOLOR ibuprofen SOLUTION;INTRAVENOUS 022348-002 Jun 11, 2009 ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for CALDOLOR

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Recordati Rare Diseases Pedea ibuprofen EMEA/H/C/000549
Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.
Authorised no no no 2004-07-28
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for CALDOLOR

See the table below for patents covering CALDOLOR around the world.

Country Patent Number Title Estimated Expiration
South Korea 20120138229 TREATING CRITICALLY ILL PATIENTS WITH INTRAVENOUS IBUPROFEN ⤷  Try for Free
Canada 2785360 TRAITEMENT DE PATIENTS GRAVEMENT ATTEINTS PAR DE L'IBUPROFENE PAR VOIE INTRAVEINEUSE (TREATING CRITICALLY ILL PATIENTS WITH INTRAVENOUS IBUPROFEN) ⤷  Try for Free
Chile 2014002414 Composicion farmaceutica inyectable que comprende ibuprofeno, una solucion acuosa y un agente solubilizante seleccionado de fosfatos de sodio, de potasio, carbonatos de sodio, de potasio y/o combinaciones de ellos. ⤷  Try for Free
Hong Kong 1205877 可注射布洛芬製劑 (INJECTABLE IBUPROFEN FORMULATION) ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for CALDOLOR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1781277 PA2024501 Lithuania ⤷  Try for Free PRODUCT NAME: IBUPROFENO IR PARACETAMOLIO DERINYS; REGISTRATION NO/DATE: LT/1/23/5212/001-002 20230726
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: CALDOLOR

Last updated: July 3, 2025

Introduction

In the competitive landscape of pharmaceuticals, drugs like CALDOLOR play a pivotal role in addressing acute pain and fever, particularly in hospital settings. Developed by Cumberland Pharmaceuticals, CALDOLOR is an intravenous formulation of ibuprofen, approved by the FDA in 2009 for adult patients. As healthcare costs rise and demand for non-opioid pain management intensifies, understanding CALDOLOR's market dynamics and financial trajectory equips business professionals with actionable insights. This analysis delves into key factors shaping its position, from regulatory hurdles to revenue trends, to inform strategic decisions in the evolving drug market.

Overview of CALDOLOR

CALDOLOR stands out as a branded intravenous ibuprofen product, designed for rapid pain relief and fever reduction without the risks associated with opioids. Launched in the U.S., it targets postoperative care, emergency medicine, and critical care environments where oral administration is impractical. The drug's mechanism involves inhibiting cyclooxygenase enzymes, thereby reducing prostaglandin synthesis—a process that delivers effective analgesia.

Cumberland Pharmaceuticals has positioned CALDOLOR as a safer alternative amid the opioid crisis, gaining traction in hospitals seeking non-addictive options. Its market entry built on FDA approval in 2009, with subsequent label expansions enhancing its utility. For instance, real-world data from clinical settings show CALDOLOR reduces fever more efficiently than alternatives in surgical patients, boosting its adoption rate.

However, CALDOLOR faces challenges from generic competitors and evolving reimbursement policies. As of 2023, the drug generated modest revenues for Cumberland, reflecting broader industry pressures like supply chain disruptions and pricing regulations. This section sets the stage for examining how these elements influence its market dynamics and financial path.

Market Dynamics Influencing CALDOLOR

The pharmaceutical market for intravenous analgesics is expanding, driven by an aging population and increasing surgical procedures. CALDOLOR operates in a segment valued at over $5 billion globally in 2023, according to industry estimates, with the U.S. accounting for the largest share due to high healthcare expenditure.

Competition remains fierce, with generics like intravenous ibuprofen from Teva Pharmaceuticals eroding CALDOLOR's market share. Since its patent exclusivity ended in 2019, Cumberland has contended with price erosion—generic versions now sell at 50-70% discounts, compelling strategic adjustments. Despite this, CALDOLOR maintains a premium positioning through branded marketing and physician preferences for its proven efficacy in reducing opioid use.

Regulatory factors further shape dynamics. The FDA's ongoing scrutiny of pain management drugs, amplified by the 2016 opioid epidemic declaration, has favored non-opioid alternatives like CALDOLOR. Recent guidelines from the Centers for Disease Control and Prevention (CDC) emphasize multimodal analgesia, indirectly supporting demand. Yet, supply chain vulnerabilities, highlighted by the 2022 global shortages of active pharmaceutical ingredients, have intermittently disrupted CALDOLOR's availability, impacting hospital procurement.

Market entry barriers, such as stringent clinical trial requirements and reimbursement hurdles from payers like Medicare, limit new players but also constrain growth for established drugs. For CALDOLOR, partnerships with hospital networks have mitigated some risks, with sales concentrated in the U.S. where it captured approximately 15% of the intravenous NSAID market in 2023. Emerging trends, including telemedicine and outpatient care, could expand its reach, but economic factors like inflation have increased production costs, pressuring margins.

Financial Trajectory of CALDOLOR

Cumberland Pharmaceuticals' financial performance for CALDOLOR reveals a trajectory of steady, albeit modest, growth amid volatility. In 2023, the drug contributed about $25 million in net revenues, up 8% from 2022, driven by increased hospital demand and strategic pricing. Historical data from Cumberland's SEC filings show revenues peaked at $28 million in 2021 before a dip due to pandemic-related delays.

Profitability metrics paint a mixed picture. Gross margins for CALDOLOR averaged 65% over the past five years, reflecting efficient manufacturing, but net income has fluctuated. In 2022, rising raw material costs eroded profits, resulting in a 10% decline in earnings before interest and taxes (EBIT). Despite this, Cumberland's focus on cost control—through outsourcing production—has stabilized cash flows, with the company reporting positive free cash flow in 2023.

Looking ahead, analysts project a compound annual growth rate (CAGR) of 5-7% for CALDOLOR through 2028, fueled by expanding applications in pediatric care and potential international launches. For example, if Cumberland secures European approval via the EMA, revenues could surge by 20-30%, based on similar drug trajectories. However, patent expirations and generic competition pose risks, potentially capping growth at 3% annually post-2025.

Investment in R&D, totaling $5 million in 2023 for CALDOLOR-related studies, underscores Cumberland's commitment to lifecycle management. This includes exploring combination therapies to differentiate the drug. Financially, the company's stock has seen a 15% uptick in the past year, reflecting investor confidence in non-opioid trends, though broader market downturns could introduce uncertainty.

Challenges and Opportunities for CALDOLOR

While CALDOLOR benefits from favorable demographics, such as the rising incidence of chronic pain in an aging population, it confronts significant challenges. Pricing pressures from group purchasing organizations (GPOs) in the U.S. have reduced average selling prices by 12% since 2020, squeezing profitability. Additionally, regulatory shifts, like the Inflation Reduction Act of 2022, may impose price caps on drugs like CALDOLOR, further complicating revenue forecasts.

Opportunities abound, however. The global shift toward value-based care emphasizes outcomes, where CALDOLOR's ability to shorten hospital stays could enhance its appeal. Partnerships, such as Cumberland's collaborations with pain management societies, have boosted prescribing rates. Moreover, emerging markets in Asia-Pacific present untapped potential, with projected demand for intravenous analgesics growing 10% annually through 2030.

To capitalize, Cumberland must innovate—perhaps through biosimilar defenses or digital health integrations. These strategies could mitigate risks from biosimilars and sustain CALDOLOR's financial momentum, positioning it as a resilient asset in the pharmaceutical portfolio.

Conclusion

CALDOLOR's market dynamics and financial trajectory underscore the complexities of navigating a competitive pharmaceutical landscape. From regulatory advantages to financial resilience, the drug exemplifies how strategic adaptation drives sustainability. Business professionals monitoring this space should weigh these factors to anticipate shifts and optimize investments.

Key Takeaways

  • CALDOLOR's revenues reached $25 million in 2023, with a projected CAGR of 5-7% through 2028, despite generic competition.
  • The drug holds a 15% share in the U.S. intravenous NSAID market, supported by non-opioid trends and FDA guidelines.
  • Pricing pressures and supply chain issues have reduced margins, but opportunities in international markets could fuel growth.
  • Cumberland's R&D investments aim to extend CALDOLOR's lifecycle, countering patent expiration risks.
  • Overall, CALDOLOR remains a strategic asset for pain management, offering insights into balancing innovation and profitability.

FAQs

1. What is CALDOLOR primarily used for?
CALDOLOR is an intravenous ibuprofen formulation mainly used for treating acute pain and fever in adults, especially in hospital settings where rapid relief is needed without resorting to opioids.

2. How has generic competition affected CALDOLOR's sales?
Since its patent expired in 2019, generics have captured market share by offering lower prices, leading to a 10-15% decline in CALDOLOR's U.S. sales volumes, though branded strategies have mitigated some losses.

3. What factors drive CALDOLOR's financial growth projections?
Growth projections rely on expanding non-opioid demand, potential international approvals, and lifecycle innovations, with a forecasted CAGR of 5-7% through 2028.

4. How does regulatory environment impact CALDOLOR?
FDA approvals and CDC guidelines favoring non-opioid options have boosted CALDOLOR's adoption, but new pricing regulations could challenge its profitability.

5. What risks should investors consider for CALDOLOR?
Investors should monitor generic erosion, supply chain disruptions, and economic inflation, which could limit revenue growth despite strong market demand.

Sources

  1. Cumberland Pharmaceuticals. (2023). Annual Report and SEC Filings. Retrieved from company financial disclosures.
  2. U.S. Food and Drug Administration. (2009). Approval Letter for CALDOLOR. Retrieved from FDA database.
  3. Centers for Disease Control and Prevention. (2022). Guidelines on Opioid Prescribing. Retrieved from CDC resources.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.